Subsidiary company "Human Coagulation Factor IX" of Beijing Tiantan Biological Products Corporation (600161.SH) will conduct phase III clinical trials.

Beijing Tiantan Biological Products Corporation (600161.SH) announced that the "Human Coagulation Factor IX" developed by its subsidiary, Chengdu Rongsheng Pharmaceutical Co., Ltd., has completed clinical ethical review, preclinical preparation for clinical enrollment, etc., and will officially start Phase III clinical trials in the near future. The main procedures that the above-mentioned product needs to complete before production and market launch include: completing Phase III clinical trials, submitting a drug marketing license application, undergoing evaluation by the Drug Evaluation Center of the National Medical Products Administration, and obtaining a drug registration certificate after approval by the National Medical Products Administration.